University of Michigan CTSA Program hub provides critical infrastructure for new precision health study using Apple Watch

The University of Michigan (U-M) recently launched a study to discover if data collected on Apple Watch (combined with other health information) can provide insight into health, wellness, and disease, and the Michigan Institute for Clinical & Health Research (MICHR), U-M’s CTSA Program hub, is providing extensive support for the study. The three-year investigation, called MIPACT (Michigan Predictive Activity and Clinical Trajectories), is already underway, with more than 2,000 participants enrolled. It aims to enroll thousands more patients of Michigan Medicine, U-M’s academic medical center, over the next year. 

MICHR’s Clinical Research Unit is providing infrastructure and clinical support to successfully enroll 700-800 participants per month, while MICHR’s Recruitment team is advising the MIPACT group on recruitment and retention strategies, providing marketing materials, training and support, and community outreach mentorship.

“Achieving the scale of this study would simply not have been possible without the infrastructure of the University of Michigan’s CTSA Program institute,” said Sachin Kheterpal, MD, MBA, co-director of the Precision Health Initiative at U-M and study lead. 

MICHR hopes this collaboration serves as an example of how CTSA Program hubs can play a critical role in impactful human health studies.

“As members of the CTSA Program, we have incredible access to best practices and materials for recruitment and retention, making us a valuable asset for community and industry partners alike,” said George A. Mashour, MD, PhD, director of MICHR. “We’re excited to be a part of this study.”

The resulting data will be made available to participants and researchers who are studying health information, daily activity, wearable signals, and participant-reported quality of life with an eye toward an improved understanding of wellness and disease. Apple is collaborating with U-M to conduct this study and a subset of the data will be available to Apple researchers.

Read the full Michigan Medicine article about this study here. If you’re interested in learning more about MICHR’s involvement, please contact Kevin Weatherwax, managing director (